Summary
AspCNU and SarCNU are two amino acid amide congeners (L-asparaginamide and sarcosinamide congeners) of chloroethylnitrosoureas. The in vitro myelotoxicity of these agents compared with BCNU at 1–8 μg/ml was determined in bone marrow cells from normal volunteers in the CFU-C assay. AspCNU and SarCNU were significantly (P<0.05) less myelotoxic than BCNU at equivalent microgram concentrations. SarCNU or AspCNU at 3 μg/ml demonstrate equivalent in vitro myelotoxicity to BCNU 1 μg/ml.
We used the human tumor stem cell assay (HTSCA) to investigate in vitro antitumor activity. We obtained four specimens of malignant glioma and one specimen of meningioma from patients not previously treated with chemotherapy. AspCNU and SarCNU were significantly (P<0.05) more active than BCNU at 1–3 μg/ml concentrations in the HTSCA in all four malignant glioma specimens. In the one meningioma specimen, BCNU was significantly (P<0.05) more active than either AspCNU or SarCNU at all concentrations studied. These results suggest that AspCNU or SarCNU at doses that should produce less myelotoxicity than BCNU may be more active than BCNU against gliomas.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- AspCNU:
-
a chloroethylnitrosourea congener of L-asparaginamide
- SarCNU:
-
a chloroethylnitrosourea congener of sarcosinamide
- BCNU:
-
bis-chloroethylnitrosourea
References
Carter SK (1973) An overview of the status of the nitrosoureas in other tumors. Cancer Chemother Rep 4: 35–46
Chabner BA, Myers CE, Oliverio VT (1977) Clinical pharmacology of anticancer drugs. Sem Oncol 4: 165–190
Christensen HN (1969) Some special kinetic problems of transport. Adv Enzymol 32: 1–20
Hamburger AW, Salmon SE (1977) Primary bioassay of human myeloma stem cells. J Clin Invest 60: 846–854
Hamburger AW, White CP, Tencer K (1982) Effect of enzymatic disaggregation on proliferation of human tumor cells in soft agar. JNCI 68: 945–949
Lam H-YP, Talgoy MM, Goldenberg GJ (1980) Uptake and decomposition of chlorozotocin in L5178Y lymphoblasts in vitro. Cancer Res 40: 3950–3955
Lazarus P, St Germain J, Dufour M, Palmer G, Wallace D, Panasci LC (1983) Comparison of the transport of chlorozotocin and CCNU in L1210 leukemia and murine bone marrow cells in vitro. Cancer Chemother Pharmacol 11: 159–161
Moon TE, Thompson SP, Salmon SE, Meyskens FL (1983) A quantitative model of the in vitro growth of melanoma cells. Proc Am Assoc Cancer Res 24: 49
Ogawa M, Bergsagel DE, McCulloch EA (1973) Sensitivity of human and murine hemopoietic precursor cells to chemotherapeutic agents assessed in cell culture. Blood 42: 851–856
Pike B, Robinson WA (1970) Human bone marrow culture in agar gel. J Cell Physiol 76: 77–84
Pratt WB, Ruddon RW (1979) New drugs and new directions in cancer chemotherapy. In: Pratt WB, Ruddon RW (eds) The anticancer drugs. Oxford University Press, New York, pp 273–276
Rosenblum ML, Gerosa MA, Wilson CB, Barger GR, Pertuiset BF, de Tribolet N, Dougherty DV (1983) Stem cell studies of human malignant brain tumors. J Neurosurg 58: 170–176
Salmon SE, Hamburger AW, Soehnlen B, Durie BG, Alberts DS, Moon TE (1978) Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med 298: 1321–1327
Salmon SE, Liu RM, Casazza AM (1981) Evaluation of new anthracycline analogs with the human tumor stem cell assay. Cancer Chemother Pharmacol 6: 103–110
Salmon SE, Young L, Sochnlen B, Liu R (1984) Antitumor activity of Esorubicin in human tumor clonogenic assay with comparisons to doxorubicin. J Clin Oncol 2: 282–286
Selby P, Buick RN, Tannock I (1983) A critical appraisal of the “human tumor stem cell assay”. N Engl J Med 308: 129–134
Snedecor GW, Cochron WC (1967) One-way classifications. Analysis of variance. In: Snedecor GW, Cochron WC (eds) Statistical methods. Iowa State University Press, Ames, pp 258–273
Shackney SE, McCormack GW, Cuchural GJ Jr (1978) Growth rate patterns of solid tumors and their relation to responsiveness to therapy. Ann Intern Med 89: 107–121
Suami T, Kato T, Takino H, Hisamatsu T (1982) (2-Chloroethyl)-nitrosourea congeners of amino acid amides. J Med Chem 25: 829–832
Vistica DT (1979) Cytotoxicity as an indicator for transport mechanism. Evidence that melphalan is transported by two leucine-preferring carrier systems in the L1210 murine leukemia cell. Biochim Biophys Acta 550: 309–317
Von Hoff DD, Clark GM, Stogdill BJ, Sarosdy MF, O'Brien MT, Casper JT, Mattox DE, Page CP, Cruz AB, Sandbach JF (1983) Prospective clinical trial of a human tumor cloning system. Cancer Res 43: 1926–1931
Walker MD (1973) Nitrosoureas in central nervous system tumors. Cancer Chemother Rep 4: 21–26
Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, Hunt WE, MacCarty GS, Mahaley MS Jr, Mealey J Jr, Owens G, Ransohoff J II, Robertson JT, Shapiro WR, Smith KR Jr, Wilson CB, Strike TA (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303: 1323–1329
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Panasci, L.C., Dufour, M., Chevalier, L. et al. Utilization of the HTSCA and CFU-C assay to identify two new 2-chloroethylnitrosourea congeners of amino acid amides with increased in vitro activity against human glioma compared with BCNU. Cancer Chemother. Pharmacol. 14, 156–159 (1985). https://doi.org/10.1007/BF00434356
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00434356